10x Genomics $TXG Stock Holdings Raised by Voya Investment Management LLC

Voya Investment Management LLC raised its stake in 10x Genomics (NASDAQ:TXG) by 24.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 95,424 shares of the company’s stock after purchasing an additional 18,635 shares during the period. Voya Investment Management LLC owned 0.08% of 10x Genomics worth $833,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of 10x Genomics by 235.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after buying an additional 4,987,195 shares during the period. Millennium Management LLC boosted its holdings in shares of 10x Genomics by 434.5% in the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock valued at $46,946,000 after buying an additional 4,371,327 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of 10x Genomics by 3,619.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock valued at $10,185,000 after buying an additional 1,135,356 shares during the period. Iron Triangle Partners LP acquired a new position in shares of 10x Genomics in the 1st quarter valued at about $8,730,000. Finally, ARK Investment Management LLC boosted its holdings in shares of 10x Genomics by 7.5% in the 1st quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company’s stock valued at $112,143,000 after buying an additional 901,656 shares during the period. Institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TXG. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, September 13th. Morgan Stanley reduced their target price on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday, August 12th. Wall Street Zen lowered shares of 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday, September 13th. Canaccord Genuity Group set a $16.00 price target on shares of 10x Genomics in a research report on Monday, August 11th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the stock a “hold” rating in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $13.65.

10x Genomics Price Performance

TXG stock opened at $12.06 on Thursday. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $23.07. The company’s 50 day simple moving average is $13.30 and its 200-day simple moving average is $10.92. The firm has a market capitalization of $1.50 billion, a P/E ratio of -17.23 and a beta of 2.00.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. The firm had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Sell-side analysts predict that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 7,486 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the sale, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,149 shares of company stock worth $539,865. Corporate insiders own 9.39% of the company’s stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.